Targets of recent warnings by the US Food and Drug Administration noting good manufacturing practices problems included OTC drug firms in South Korea about acne treatments and a Chinese company about
New drug good manufacturing practice warning letters trickled onto the US Food and Drug Administration’s web site even as the agency further extended a year-end inspection hiatus due to a resurgent pa